NE-3107 is a Small Molecule owned by BioVie, and is involved in 9 clinical trials, of which 6 were completed, 1 is ongoing, and 2 are planned. NE-3107 (Triolex, HE3286) acts by inhibiting extracellular signal regulated kinase 1 and 2. The drug candidate by inhibiting ERK 1 & 2, inhibits the activity of major inflammatory mediators ERK, NFKappaB and TNF in pathology specific signaling pathways, without inhibiting homeostatic function and elicits the therapeutic intervention. 

The revenue for NE-3107 is expected to reach a total of $983m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the NE-3107 NPV Report.

NE-3107 was originated by Harbor Therapeutics and is currently owned by BioVie.

NE-3107 Overview

NE-3107 (Triolex, HE3286) is under development for the treatment of Alzheimer's disease, multiple myeloma, early stage prostate cancer, castration resistant prostate cancer and Parkinson's disease. The drug candidate is administered through oral route. The drug candidate is developed based on hormonal signaling technology platform. It acts by targeting ERK 1AND 2 (Extracellular Signal Regulated Kinase 1 and 2). The drug candidate was also under development for the treatment of inflammatory diseases, systemic lupus erythematosus, cystic fibrosis, type 2 diabetes, L-dopa induced dyskinesia, rheumatoid arthritis, ulcerative colitis and  multiple sclerosis.

BioVie Overview

BioVie (BIVI) is a clinical-stage biopharmaceutical company that develops drug therapies for liver disease. The company’s pipeline products such as BIV201 (continuous infusion terlipressin) and clinical trial for ascites due to advanced liver cirrhosis. BIV201 for hepatorenal syndrome (HRS). It focused on potential future treatment option patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, NASH and alcoholism. The company is also focused on the FDA to approve their drug specifically for treating ascites to extend their quality. BioVie is targeting this landmark achievement. BIVI is headquartered in Santa Monica, California, the US.

The operating loss of the company was US$27.3 million in FY2022, compared to an operating loss of US$138 million in FY2021. The net loss of the company was US$26.1 million in FY2022, compared to a net loss of US$130.3 million in FY2021.

Quick View – NE-3107

Report Segments
  • Innovator
Drug Name
  • NE-3107
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Immunology
  • Metabolic Disorders
  • Oncology
  • Ophthalmology
  • Respiratory
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.